TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36103386
Drug: Alfaxalone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (5 mg/kg, IM) + Physiologic saline (0.5 mL, IM)
Study: 36103386
Drug: Medetomidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Study: 36103386
Drug: Medetomidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Study: 36103386
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Study: 36103386
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Study: 33308198
Drug: Tailored antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored antihypertensive medication based on mean arterial pressure/heart rate ratio
Study: 35708709
Drug: SMILE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMILE regimen (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Study: 32491956
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), 2 sessions applied to pain points with a 48-hr interval
Study: 32491956
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, 2 sessions applied to pain points with a 48-hr interval
Study: 32594451
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg OD
Study: 32594451
Drug: Hydroxychloroquine 300
Normalized name: hydroxychloroquine 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 300 mg OD
Study: 32594451
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg OD
Study: 32594451
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg BD
Study: 32305572
Drug: 1 ng/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ng/kg LPS intravenous administration
Study: 32305572
Drug: 2 ng/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ng/kg LPS intravenous administration
Study: 34319940
Drug: Citrulline-Malate (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline-Malate (8 g CM + 12 g dextrose)
Study: 35432695
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400mcg
Study: 35745198
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day bovine lactoferrin (bLF) for 3 weeks (T2)
Study: 35745198
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day bLF and 2.64 g/day active galactooligosaccharides (GOS) for 3 weeks (T3)
Study: 35745198
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day bLF, 2.64 g/day GOS and 20 μg/day vitamin D for 3 weeks (T4)
Study: 33101444
Drug: Qingshen granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingshen granules (three times daily for 12 weeks)
Study: 33101444
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical therapy (control group)
Study: 35716319
Drug: DE-089C (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-089C (long-acting diquafosol ophthalmic solution), administered three times daily for 4 weeks
Study: 35716319
Drug: Placebo ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution, administered three times daily for 4 weeks
Study: 35942886
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact (SSC) for one hour daily from birth until postnatal week five
Study: 33096291
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy + PE‐FMR
Study: 33096291
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy + DE
Study: 33096291
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy + PE‐FMR + DE
Study: 35706488
Drug: Active symptom
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active symptom control with oral vinorelbine (ASC + vinorelbine)
Study: 33431242
Drug: Diabetes medication-taking
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes medication-taking behavior
Study: 33431242
Drug: Medication-taking behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-taking behavior
Study: 34106303
Drug: Subcutaneous pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous pertuzumab and trastuzumab (PH FDC SC)
Study: 34106303
Drug: Intravenous pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous pertuzumab and trastuzumab
Study: 32725178
Drug: Improving Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improving Pain During Addiction Treatment (ImPAT)
Study: 36440097
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 32 mg once daily)
Study: 32761160
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 40 mg once daily)
Study: 32727336
Drug: Antithyroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid therapy (thioamides and/or surgical therapy)
Study: 32727336
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (group 2, n=9)
Study: 32727336
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (group 1, n=62)
Study: 33206462
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal ring (25 mg)
Study: 35477992
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (UFH)
Study: 35810277
Drug: Ceftriaxone (CRO)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CRO) 1 g IV + Doxycycline (DOX)
Study: 35810277
Drug: Cefixime (CFM)
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime (CFM) 800 mg oral + Doxycycline (DOX)
Study: 33957004
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds oil (2.5 ml twice daily for 8 weeks)
Study: 32951358
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg or 10 mg/kg for body weight <30 kg; 8 mg/kg for body weight ≥30 kg) administered intravenously every 4 weeks for 16 weeks, followed by random assignment to tocilizumab or placebo.
Study: 34597729
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 (VDZ)
Study: 34597729
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 plus an additional dose at week 10 (VDZ + wk10)
Study: 34406312
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) users
Study: 34406312
Drug: Prophylactic-dose LMWH
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic-dose LMWH users
Study: 34406312
Drug: Intermediate-dose LMWH
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose LMWH users (based on biomarkers)
Study: 34406312
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of anticoagulants
Study: 32757418
Drug: Sweet-tasting solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet-tasting solution
Study: 34271362
Drug: Duloxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40 mg BID) + innovative pelvic floor muscle training (iPFMT) with lumbopelvic stabilization
Study: 34271362
Drug: Oral duloxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral duloxetine treatment (40 mg BID)
Study: 32253184
Drug: Bimekizumab 16
Normalized name: Bimekizumab 160 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 16 mg
Study: 35379598
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg intravenous tocilizumab (Group 1)
Study: 35379598
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg intravenous tocilizumab (Group 2)
Study: 35379598
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of intravenous tocilizumab
Study: 33454995
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptives (COCs)
Study: 34044355
Drug: I-Gel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-Gel®
Study: 35046189
Drug: Intermaxillary fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermaxillary fixation (IMF) screw therapy
Study: 35046189
Drug: Placebo (intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intraarticular saline injection)
Study: 32173375
Drug: gp120 trimers
Normalized name: glyoxal trimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120 trimers bound to BLPs delivered via intranasal (i.n.) drip
Study: 33131314
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP <120 mm Hg)
Study: 34528337
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (7 days of omeprazole + amoxicillin followed by 7 days of omeprazole + clarithromycin + metronidazole)
Study: 36478192
Drug: Active distraction
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active distraction using video games on a tablet device and wireless joystick (VG)
Study: 36478192
Drug: Passive distraction
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive distraction using video on tablet and wireless headphones (AV)
Study: 33169240
Drug: Citicoline 10
Normalized name: citicoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 10 mg/kg/12h IV for 6 weeks plus supportive measures
Study: 32455493
Drug: Prehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehydration with 1.5 L of water within 1 hour before uroflowmetry
Study: 32103603
Drug: Autologous skin
Normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skin cell suspension (ASCS) + compression therapy
Study: 32103603
Drug: Standard compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard compression therapy (Control)
Study: 615704460
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ALA administered to recipients and graft perfused with 600 mg of ALA 1 hour before surgery
Study: 38293957
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg
Study: 35920936
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ICG
Study: 35920936
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg ICG
Study: 35920936
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ICG
Study: 35920936
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ICG
Study: 35655234
Drug: 6% Hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl Starch (HES) 130 solution (Volulyte 6%)
Study: 35655234
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution (Ionolyte)
Study: 35308505
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 3000 IU/d oral spray supplementation
Study: 33620551
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of a multivitamin tablet with 150 μg of iodine
Study: 33620551
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of a multivitamin tablet without iodine
Study: 32980142
Drug: Norepinephrine 5 μg.mL−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 5 μg.mL−1 (n = 40)
Study: 32980142
Drug: Epinephrine 5 μg.mL−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 5 μg.mL−1 (n = 40)
Study: 32980142
Drug: Phenylephrine 100 μg.mL−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg.mL−1 (n = 40)
Study: 32980142
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusions (n = 40)
Study: 34561142
Drug: Engerix-B vaccine
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B vaccine
Study: 35771219
Drug: Home-based leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based leg heat therapy (HT) using water-circulating trousers, 90 min/session, 7 days/week for 8 weeks
Study: 34154590
Drug: Relugolix 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix 10 mg
Study: 34154590
Drug: Relugolix 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix 20 mg
Study: 34154590
Drug: Relugolix 40
Normalized name: relugolix 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix 40 mg
Study: 34154590
Drug: Leuprorelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 3.75 mg
Study: 36178636
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step count
Study: 34989637
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a tourniquet and buffered lidocaine solution (CTB)
Study: 34496924
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical treatment (control group)
Study: 34015311
Drug: Neoadjuvant durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant durvalumab monotherapy
Study: 34953451
Drug: Swedish massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish massage (30-min sessions, twice a week for first 4 weeks, three times a week for last 4 weeks)
Study: 32989866
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment once a week (Group 1)
Study: 32989866
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment twice a week (Group 2)
Study: 32989866
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy once a week (Group 3)
Study: 34031890
Drug: Prednisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (50 mg for 7 days)
Study: 33992438
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6)
Study: 33992438
Drug: Chinese hamster
Normalized name: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6)
Study: 33992438
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6)
Study: 32602970
Drug: TARC-2 >800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARC-2 >800 pg/mL
Study: 32602970
Drug: TARC-2 ≤800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARC-2 ≤800 pg/mL
Study: 32602970
Drug: TARC-2 >800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARC-2 >800 pg/mL (whole study population)
Study: 32602970
Drug: TARC-2 >800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARC-2 >800 pg/mL (PET-2-negative patients)
Study: 36281170
Drug: Low-dose doxepin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxepin (6.25 mg-12.5 mg per day) for 12 weeks
Study: 33518123
Drug: Temperature/RH combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature/RH combination of -15°C with uncontrolled RH for 8 hours
Study: 33518123
Drug: Temperature/RH combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature/RH combination of 30°C with 80% RH for 8 hours
Study: 33518123
Drug: Temperature/RH combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature/RH combination of 30°C with 30% RH for 8 hours
Study: 35446986
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for PTSD
Study: 35446986
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for PTSD and depression
Study: 35676030
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid (ω3FA) supplementation (4 g/day)
Study: 35676030
Drug: No ω3FA
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ω3FA treatment (Control)
Study: 33966671
Drug: 1‐minute ultraviolet‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐minute ultraviolet‐C light (UV‐C) treatment prior to donning
Study: 32998766
Drug: Ferritin-guided donation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin-guided donation intervals policy (including ferritin measurements for all new donors and at every 5th whole blood donation, extending donation intervals to 6 months if ferritin is 15-≤ 30 ng/mL and to 12 months if ferritin is < 15 ng/mL)
Study: 35334862
Drug: High-dose whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose whey protein concentrate (WPC)
Study: 38777128
Drug: Tirzepatide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (all doses)
Study: 36104378
Drug: Luseogliflozin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (2.5 mg daily)
Study: 36104378
Drug: Voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.6 mg daily)
Study: 35418599
Drug: Selenite 6
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 6 mg/l
Study: 35418599
Drug: Selenite 8
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 8 mg/l
Study: 35418599
Drug: Selenite 10
Normalized name: sodium selenite 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 10 mg/l
Study: 35418599
Drug: Nano-selenium 12
Normalized name: selenious acid
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-selenium 12 mg/l
Study: 35418599
Drug: Selenite 6
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite 6 mg/l and 8 mg/l
Study: 34022796
Drug: Vonoprazan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (20 mg/day)
Study: 34022796
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg/day)
Study: 32031904
Drug: HIV patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV patients accessing antiretroviral treatment
Study: 35768650
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W)
Study: 33567129
Drug: Raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (3 mg/m2 from day 1 every 3 weeks) and oral S‐1 (80‐120 mg for 14 days every 3 weeks)
Study: 35666800
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg of 0.1% E2 gel daily
Study: 36951827
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg once daily
Study: 35031887
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (415 mg)
Study: 34238546
Drug: Haemodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodynamic therapy to achieve individualised preoperative DO2
Study: 35303025
Drug: Higher initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher initial levels of other drug use
Study: 34812863
Drug: Intra-articular Platelet-Rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Platelet-Rich Plasma (PRP) injections (n=144 participants)
Study: 34812863
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injections (n=144 participants)
Study: 34475964
Drug: Qishen Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi dripping pills (QSYQ) for 12 weeks
Study: 32275024
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural (TEA) with 0.25% bupivacaine and continuous infusion of 0.1% bupivacaine with 2 mcg/ml of fentanyl.
Study: 32275024
Drug: Intercostal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal block (ICN) with 0.25% bupivacaine and continuous intravenous morphine infusion of 0.015‐0.02 mg/kg/hr.
Study: 34020205
Drug: Active iTBS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active iTBS (1200 pulses per session, twice daily over ten weekdays)